Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
Summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Official title: GENESIS: AIMOVIG® Pregnancy Exposure Registry
Key Details
Gender
FEMALE
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
2842
Start Date
2021-01-27
Completion Date
2027-10-28
Last Updated
2025-11-04
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
erenumab-aooe
Dose and treatment duration will be advised by the HCP
Locations (1)
IQVIA Virtual Site
Durham, North Carolina, United States